The Effects of Enzyme-rich Malt Extract on Chronic Constipation
NCT ID: NCT04873466
Last Updated: 2022-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2021-03-01
2022-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fiber Tolerability in Children
NCT02519374
Impact of Improving Gastrointestinal Symptoms on Autism Symptoms and Oxidative Stress
NCT02442115
Predictors of Constipation in Healthy Children
NCT00398021
Three Dietary Regimens in Pre-colonoscopic Bowel Preparation in Children
NCT05609591
Review of Enteral Formulas in Children
NCT04247269
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study involves eligible participants that have a diagnosis constipation according to the Knowles-Eccersley-Scott Score (KESS). Participants will receive intervention with a food supplement enzyme-rich malt extract (ERME) at a dose of 15ml twice daily with food.
Before intervention commences, participants will complete baseline breath samples and a 7 day stool diary to assess stool frequency and consistency.
Participants will then receive the ERME as instructed and continue to complete a bowel diary. Then at 4 weeks since starting the intervention, participants will provide another breath sample and complete another set of breath samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Enzyme-rich malt extract
Enzyme-rich malt extract (15 ml b.i.d with food)
Enzyme-rich malt extract
Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enzyme-rich malt extract
Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant can communicate and understand English.
* Participant has a body mass index (BMI) between 18.5 and 34.9kg/m2 (bounds included).
Exclusion Criteria
* New use of prokinetic therapy during the study.
* Use of antibiotics in the last 4 weeks.
* Use of probiotics in the last 2 weeks.
* Organic gastrointestinal disease, including inflammatory bowel disease (IBD), coeliac disease and diverticulitis.
* Participant has known mechanical obstruction of the GI tract.
* Participant has diabetes.
* Participant has any hepatic disease.
* Participant has any disease of the CNS.
* Participant has had previous abdominal or colorectal surgery including appendectomy, cholecystectomy, and hysterectomy.
* Participant has intake of ERME for 2 weeks before the study.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Functional Gut Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jordan Haworth
Clinical Physiologist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Functional Gut Clinic
Manchester, Greater Manchester, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FGC-20-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.